We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-2.45%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$364M
AUM Growth
-$19.7M
Cap. Flow
-$6.77M
Cap. Flow %
-1.86%
Top 10 Hldgs %
44.42%
Holding
83
New
22
Increased
23
Reduced
12
Closed
26

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$17.9M
2
ICLR icon
Icon
ICLR
+$17.1M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14M
4
THC icon
Tenet Healthcare
THC
+$13.5M
5
RCM
R1 RCM Inc. Common Stock
RCM
+$10.6M

Top Sells

Rank Stock Value
1
KIDS icon
OrthoPediatrics
KIDS
+$19.3M
2
AHCO icon
AdaptHealth
AHCO
+$14.7M
3
SNY icon
Sanofi
SNY
+$13.5M
4
BDX icon
Becton Dickinson
BDX
+$13.2M
5
CVS icon
CVS Health
CVS
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 80.17%
2 Industrials 3.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLU
51
DELISTED
BELLUS Health Inc.
BLU
$1.26M 0.35%
406,537
+92,702
+30% +$354K
CYAD
52
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$845K 0.23%
+160,691
New +$960K
CANO
53
DELISTED
Cano Health, Inc.
CANO
$750K 0.21%
+620
New +$836K
PRVB
54
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$699K 0.19%
+82,960
New +$669K
XFOR icon
55
X4 Pharmaceuticals
XFOR
$405M
$461K 0.13%
2,366
-2,701
-53% -$679K
AFMD
56
DELISTED
Affimed
AFMD
– –
-33,067
Closed -$2.62M
AHCO icon
57
AdaptHealth
AHCO
$913M
– –
-399,730
Closed -$14.7M
ANGO icon
58
AngioDynamics
ANGO
$628M
– –
-128,865
Closed -$3.02M
ATNM icon
59
CALL
Actinium Pharmaceuticals
ATNM
$25.4M
– –
-2,000,000
Closed -$15.2M
AZN icon
60
AstraZeneca
AZN
$241B
– –
-119,050
Closed -$11.8M
BDX icon
61
Becton Dickinson
BDX
$46.9B
– –
-55,714
Closed -$13.2M
BOLT icon
62
Bolt Biotherapeutics
BOLT
$7.59M
– –
-889
Closed -$585K
BSX icon
63
Boston Scientific
BSX
$71.1B
– –
-158,702
Closed -$6.13M
CNC icon
64
Centene
CNC
$31.7B
– –
-76,551
Closed -$4.89M
CVS icon
65
CVS Health
CVS
$133B
– –
-167,362
Closed -$12.6M
DVA icon
66
DaVita
DVA
$14.6B
– –
-23,930
Closed -$2.58M
EHC icon
67
Encompass Health
EHC
$11B
– –
-168,188
Closed -$11M
ESPR
68
DELISTED
Esperion Therapeutics
ESPR
– –
-55,540
Closed -$1.56M
GDRX icon
69
GoodRx Holdings
GDRX
$1.13B
– –
-136,480
Closed -$5.33M
IRON icon
70
Disc Medicine
IRON
$2.99B
– –
-5,663
Closed -$2.3M
KIDS icon
71
OrthoPediatrics
KIDS
$536M
– –
-396,162
Closed -$19.3M
MCK icon
72
McKesson
MCK
$97.2B
– –
-44,132
Closed -$8.61M
MRVI icon
73
Maravai LifeSciences
MRVI
$948M
– –
-58,168
Closed -$2.07M
SNY icon
74
Sanofi
SNY
$102B
– –
-272,218
Closed -$13.5M
STRM
75
DELISTED
Streamline Health Solutions
STRM
– –
-25,894
Closed -$796K
1 2
3
4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Endurant Capital Management held 83 positions worth $364M, down 5.1% from $384M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Endurant Capital Management's Q2 2021 filing shows 22 new, 23 increased, 12 reduced and 26 closed positions. Its largest new stake was Cigna: 71,856 shares worth $17M. The largest sale was OrthoPediatrics, an estimated $19.3M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 86% a quarter earlier, followed by Industrials.

  • Endurant Capital Management's largest Q2 2021 buy was Cigna: 71,856 shares worth $17M.
  • Endurant Capital Management added most to R1 RCM Inc. Common Stock in Q2 2021, an estimated $10.6M increase.
  • Endurant Capital Management's biggest Q2 2021 reduction was Bristol-Myers Squibb, cutting an estimated $8.66M.
  • Endurant Capital Management fully exited OrthoPediatrics in Q2 2021, selling an estimated $19.3M.
  • Endurant Capital Management's ten largest holdings make up 44% of its $364M portfolio in Q2 2021.
  • Endurant Capital Management opened 22 new positions and closed 26 in Q2 2021.
  • Endurant Capital Management's portfolio value fell 5.1% quarter-over-quarter to $364M.

Based on Endurant Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.